Evidence map›Paper›PMID 33803811›Full record

ArticleViruses2021

Treatment Protocol for COVID-19 Based on T2R Phenotype.

Mohamed A Taha, Christian A Hall, Colin J Shortess, Richard F Rathbone, Henry P Barham

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05520944 (Accelerating COVID-19 Clinical Recovery in the Outpatient Setting), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05520944 unknown statusnot on this map

Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Data Collection and Analysis of COVID-19 Patients Treated With ClorNovir® (Chlorpheniramine Maleate (0.4% Nasal Spray)

TypeobservationalSponsorDr. Ferrer BioPharmaRan2021 to 2022Enrolled1,000ConditionsCOVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS CoV 2 InfectionArmsClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Extragustatory bitter taste receptors in head and neck health and disease.Journal of molecular medicine (Berlin, Germany) · 2024
    Review
  4. Review
  5. Article
  6. Article
  7. COVID-19 in 2021.Viruses · 2021
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohamed A TahaRhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.ORCID 0000-0002-7745-4727
Christian A HallRhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.
Colin J ShortessRhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.
Richard F RathboneRhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.
Henry P BarhamRhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 has become a global pandemic of the highest priority. Multiple treatment protocols have been proposed worldwide with no definitive answer for acure. A prior retrospective study showed association between bitter taste receptor 38 (T2R38) phenotypes and the severity of COVID-19. Based on this, we proposed assessing the different T2R38 phenotypes response towards a targeted treatment protocol. Starting July 2020 till December 2020, we tested subjects for T2R38 phenotypic expression (supertasters, tasters, and nontasters). Subjects who were subsequently infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (diagnosed via PCR) were included. Based on their taster status, supertasters were given dexamethasone for 4 days; tasters were given azithromycin and dexamethasone +/- hydroxychloroquine for 7 days; and nontasters were given azithromycin and dexamethasone for 12 days. Subjects were followed prospectively and their outcomes were documented. Seven hundred forty-seven COVID-19 patients were included, with 184 (24.7%) supertasters, 371 (49.6%) tasters, and192 (25.7%) nontasters. The average duration of symptoms with the treatment protocol was 5 days for supertasters, 8.1 days for tasters, and 16.2 days for nontasters. Only three subjects (0.4%) required hospitalization (3/3 nontasters). Targeted treatment protocol showed significant correlation (

Indexed as

Clinical ProtocolsCOVID-19 Drug TreatmentAdultAzithromycinCOVID-19DexamethasoneFemaleHumansMaleMiddle AgedPhenotypeProspective StudiesReceptors, G-Protein-CoupledRetrospective StudiesSARS-CoV-2TasteAzithromycinDexamethasoneReceptors, G-Protein-CoupledTaste Receptors, Type 2bitter taste receptorsCOVID-19solitary chemosensory cellsT2R38

Identifiers

PMID33803811
PMCPMC8003114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.